ATE391126T1 - Kristalline form des (r)-2-(((3-methyl-4-(2,2,2- trifluorethoxy)-2-pyridinyl)methyl)sulfinyl)-1h benzimidazols - Google Patents

Kristalline form des (r)-2-(((3-methyl-4-(2,2,2- trifluorethoxy)-2-pyridinyl)methyl)sulfinyl)-1h benzimidazols

Info

Publication number
ATE391126T1
ATE391126T1 AT00937235T AT00937235T ATE391126T1 AT E391126 T1 ATE391126 T1 AT E391126T1 AT 00937235 T AT00937235 T AT 00937235T AT 00937235 T AT00937235 T AT 00937235T AT E391126 T1 ATE391126 T1 AT E391126T1
Authority
AT
Austria
Prior art keywords
methyl
trifluorethoxy
sulfinyl
benzimidazole
pyridinyl
Prior art date
Application number
AT00937235T
Other languages
English (en)
Inventor
Akira Fujishima
Isao Aoki
Keiji Kamiyama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15924444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE391126(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE391126T1 publication Critical patent/ATE391126T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00937235T 1999-06-17 2000-06-15 Kristalline form des (r)-2-(((3-methyl-4-(2,2,2- trifluorethoxy)-2-pyridinyl)methyl)sulfinyl)-1h benzimidazols ATE391126T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17150999 1999-06-17

Publications (1)

Publication Number Publication Date
ATE391126T1 true ATE391126T1 (de) 2008-04-15

Family

ID=15924444

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00937235T ATE391126T1 (de) 1999-06-17 2000-06-15 Kristalline form des (r)-2-(((3-methyl-4-(2,2,2- trifluorethoxy)-2-pyridinyl)methyl)sulfinyl)-1h benzimidazols

Country Status (27)

Country Link
US (11) US6462058B1 (de)
EP (3) EP1129088B1 (de)
KR (3) KR100514204B1 (de)
CN (1) CN1150186C (de)
AR (5) AR031069A1 (de)
AT (1) ATE391126T1 (de)
AU (1) AU778820B2 (de)
BE (1) BE2014C017I2 (de)
BR (1) BRPI0011674B8 (de)
CA (1) CA2375201C (de)
CY (2) CY1110384T1 (de)
DE (1) DE60038481T2 (de)
DK (2) DK1977751T3 (de)
ES (2) ES2426985T3 (de)
HK (2) HK1038227A1 (de)
HU (1) HU229067B1 (de)
IL (2) IL145996A0 (de)
MX (1) MXPA01012642A (de)
MY (1) MY125399A (de)
NO (1) NO321168B1 (de)
NZ (1) NZ515702A (de)
PL (1) PL201068B1 (de)
PT (2) PT1977751E (de)
SI (1) SI1129088T1 (de)
TW (2) TWI275587B (de)
WO (2) WO2004083200A1 (de)
ZA (1) ZA200108331B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60020967T2 (de) * 1999-06-30 2006-05-04 Takeda Pharmaceutical Co. Ltd. Kristalle von lansoprazole
AU2001252595A1 (en) 2000-04-28 2001-11-12 Takeda Chemical Industries Ltd. Process for producing optically active sulfoxide derivative
ES2511774T3 (es) * 2000-05-15 2014-10-23 Takeda Pharmaceutical Company Limited Formas cristalinas de (R)-lansoprazol
CA2775616C (en) * 2000-08-04 2013-09-17 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
US7285668B2 (en) * 2000-12-01 2007-10-23 Takeda Pharmaceutical Company Limited Process for the crystallization of (R)- or (S)-lansoprazole
US8105626B2 (en) 2001-10-17 2012-01-31 Takeda Pharmaceutical Company Limited Granules containing acid-unstable chemical in large amount
KR100467100B1 (ko) * 2002-03-20 2005-01-24 일양약품주식회사 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법
KR20040093187A (ko) * 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 란소프라졸 다형 및 그것의 제조 방법
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CN100364987C (zh) * 2003-03-24 2008-01-30 卫材R&D管理有限公司 亚砜衍生物或其盐的非定形态的制备方法
CA2529255A1 (en) * 2003-06-20 2004-12-29 Ch Chemicals (Pty) Ltd Polyurethane-based cementitious liner
AR045061A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
EP2264025B1 (de) 2004-09-13 2013-11-06 Takeda Pharmaceutical Company Limited Verfahren zur Herstellung von Lansoprazole
WO2006090845A1 (ja) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited 顆粒の製造方法
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
CN101389316A (zh) 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
KR100758600B1 (ko) * 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2089379A4 (de) * 2006-12-07 2010-04-21 Hetero Drugs Ltd Neue kristalline form von lansoprazol
JP5366558B2 (ja) 2006-12-28 2013-12-11 武田薬品工業株式会社 口腔内崩壊性固形製剤
CN102014638A (zh) * 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
NZ585944A (en) * 2007-12-18 2011-11-25 Watson Pharma Private Ltd A process for preparation of stable amorphous R-(+)-lansoprazole
JP2011507977A (ja) * 2007-12-31 2011-03-10 武田薬品工業株式会社 （ｒ）−２−［［［３−メチル−４−（２，２，２−トリフルオロエトキシ）−２−ピリジニル］メチル］スルフィニル］−１ｈ−ベンズイミダゾールの溶媒和物結晶形
JP2011513202A (ja) 2008-03-10 2011-04-28 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
GEP20135845B (en) * 2008-03-11 2013-06-10 Takeda Pharmaceutical Orally-disintegrating solid formulation
US20110028518A1 (en) * 2008-03-18 2011-02-03 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
NZ589150A (en) * 2008-05-14 2012-03-30 Watson Pharma Private Ltd Stable r (+) -lansoprazole amine salt and a process for preparing the same
PE20110591A1 (es) * 2008-07-28 2011-09-15 Takeda Pharmaceutical Composicion farmaceutica estabilizada a base de un compuesto no peptidico
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
IT1391758B1 (it) * 2008-11-11 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo amorfo
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
EP2498782B1 (de) 2009-11-12 2019-01-09 Pharmatrophix Inc. Kristalline formen aus neurotrophinmimetischen verbindungen und ihren salzen
CN102108076B (zh) * 2009-12-23 2014-07-23 江苏豪森医药集团有限公司 制备无定形右兰索拉唑的方法
US20130197232A1 (en) 2010-01-29 2013-08-01 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
CA2795056C (en) 2010-03-31 2015-03-24 Ranbaxy Laboratories Limited Salts of dexlansoprazole and their preparation
WO2011121548A1 (en) 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
EP2384746A3 (de) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Orale Tablettenzusammensetzungen aus Dexlansoprazol mit dualer Freisetzung
EP2384747A3 (de) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Orale Tablettenzusammensetzungen aus Dexlansoprazol
EP2384745A3 (de) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmazeutische Zusammensetzungen mit modifizierter Freisetzung aus Dexlansoprazol
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
KR101908748B1 (ko) 2010-12-03 2018-10-16 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴정
SG10201602311XA (en) 2010-12-27 2016-04-28 Takeda Pharmaceutical Orally disintegrating tablet
EP2663306A4 (de) * 2011-01-12 2014-01-01 Hetero Research Foundation Polymorphe aus dexlansoprazolsalzen
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
WO2012176140A1 (en) * 2011-06-21 2012-12-27 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102875531B (zh) * 2011-07-15 2015-08-19 上海睿智化学研究有限公司 一种(r)-兰索拉唑无水晶型及其制备方法
CN102875530A (zh) * 2011-07-15 2013-01-16 上海睿智化学研究有限公司 一种(r)-兰索拉唑叔丁胺盐及其晶型和制备方法
CN102875532B (zh) * 2011-07-15 2015-05-13 上海睿智化学研究有限公司 一种(r)-兰索拉唑异丙胺盐及其晶型和制备方法
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
EP2785331B1 (de) 2011-11-30 2015-11-18 Takeda Pharmaceutical Company Limited Trockenbeschichtete tablette
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN103709139B (zh) * 2012-10-09 2016-12-21 上海汇伦生命科技有限公司 无水右兰索拉唑的制备方法
CN104177333A (zh) * 2013-05-24 2014-12-03 四川海思科制药有限公司 一种理化性质稳定的(r)-2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1h-苯并咪唑
CN104650035A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 右兰索拉唑倍半水合物化合物
CN103664889B (zh) * 2013-12-19 2014-11-19 悦康药业集团有限公司 一种兰索拉唑化合物
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
EP2929885A1 (de) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmazeutische kombinationen von rivaroxaban und protonenpumpenhemmern
CN104844576B (zh) * 2015-04-28 2017-03-08 山东罗欣药业集团股份有限公司 一种兰索拉唑或右旋兰索拉唑晶型化合物及其制备方法
CN104829594A (zh) * 2015-05-15 2015-08-12 苗怡文 一种治疗胃溃疡的药物兰索拉唑化合物
CN105017218A (zh) * 2015-07-01 2015-11-04 合肥安德生制药有限公司 一种右兰索拉唑晶型及其制备方法
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997738A (zh) * 2015-08-10 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物兰索拉唑组合物干混悬剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN108164507A (zh) * 2016-12-07 2018-06-15 天津药物研究院有限公司 一种右兰索拉唑单晶及其制备方法和用途
TR201701461A2 (tr) 2017-01-31 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dekslansoprazolün Enterik Kaplı Farmasötik Kompozisyonları
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN107011329A (zh) * 2017-05-05 2017-08-04 广州大光制药有限公司 兰索拉唑一水合物晶型及其结晶制备方法
CN108794450B (zh) * 2018-07-24 2022-08-19 浙江恒康药业股份有限公司 制备无定型右旋兰索拉唑的方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
AU5652698A (en) 1996-11-12 1998-06-03 Byk Gulden Lomberg Chemische Fabrik Gmbh (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
CN1238694A (zh) * 1996-11-22 1999-12-15 普罗克特和甘保尔公司 治疗肠胃病用的含铋和nsaid的组合物
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
WO1999038512A1 (en) 1998-01-30 1999-08-05 Sepracor Inc. S-lansoprazole compositions and methods
EP1056456A4 (de) 1998-01-30 2006-10-25 Sepracor Inc R-lansoprazol zusammenstellungen und behandlungen damit
WO1999056698A2 (en) * 1998-05-06 1999-11-11 Københavns Universitet Treatment of celiac disease
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60020967T2 (de) * 1999-06-30 2006-05-04 Takeda Pharmaceutical Co. Ltd. Kristalle von lansoprazole
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法
AU2003273000A1 (en) * 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
CN100364987C (zh) * 2003-03-24 2008-01-30 卫材R&D管理有限公司 亚砜衍生物或其盐的非定形态的制备方法
CA2591983A1 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
CN101111233A (zh) * 2004-12-23 2008-01-23 兰贝克赛实验室有限公司 稳定的口服苯并咪唑组合物及其制备方法
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
NZ585944A (en) * 2007-12-18 2011-11-25 Watson Pharma Private Ltd A process for preparation of stable amorphous R-(+)-lansoprazole

Also Published As

Publication number Publication date
US7737282B2 (en) 2010-06-15
TWI289557B (en) 2007-11-11
KR20030068592A (ko) 2003-08-21
US20040048898A1 (en) 2004-03-11
US6939971B2 (en) 2005-09-06
IL145996A0 (en) 2002-07-25
US6664276B2 (en) 2003-12-16
US20120316344A1 (en) 2012-12-13
EP1129088A2 (de) 2001-09-05
US20080132547A1 (en) 2008-06-05
EP1129088B1 (de) 2008-04-02
PT1977751E (pt) 2013-08-01
US20150025115A1 (en) 2015-01-22
HUP0201659A3 (en) 2003-11-28
PL352193A1 (en) 2003-08-11
AU778820B2 (en) 2004-12-23
HK1123985A1 (en) 2009-07-03
DE60038481D1 (de) 2008-05-15
WO2000078745A2 (en) 2000-12-28
AU5247800A (en) 2001-01-09
KR100537029B1 (ko) 2005-12-16
US20140012006A1 (en) 2014-01-09
WO2000078745A3 (en) 2001-07-05
HU229067B1 (en) 2013-07-29
CY1110384T1 (el) 2015-04-29
US20110319450A1 (en) 2011-12-29
ES2300265T3 (es) 2008-06-16
PL201068B1 (pl) 2009-03-31
WO2004083200A1 (en) 2004-09-30
US20050228026A1 (en) 2005-10-13
MY125399A (en) 2006-07-31
US20030045724A1 (en) 2003-03-06
BE2014C017I2 (de) 2019-05-21
BRPI0011674B1 (pt) 2017-05-30
DK1129088T3 (da) 2008-06-09
AR103295A2 (es) 2017-05-03
ZA200108331B (en) 2002-10-10
MXPA01012642A (es) 2002-07-22
AR100473A2 (es) 2016-10-12
AR079473A2 (es) 2012-01-25
KR100407847B1 (ko) 2003-12-01
US9145389B2 (en) 2015-09-29
EP1977751A1 (de) 2008-10-08
DK1977751T3 (da) 2013-09-02
US6462058B1 (en) 2002-10-08
US7569697B2 (en) 2009-08-04
HK1038227A1 (en) 2002-03-08
AR031069A1 (es) 2003-09-10
CN1150186C (zh) 2004-05-19
EP1977751B1 (de) 2013-07-24
US20100222391A1 (en) 2010-09-02
NO321168B1 (no) 2006-03-27
IL145996A (en) 2008-07-08
US8884019B2 (en) 2014-11-11
US8030333B2 (en) 2011-10-04
KR100514204B1 (ko) 2005-09-13
CN1355798A (zh) 2002-06-26
CY1114485T1 (el) 2017-01-25
CA2375201C (en) 2010-02-09
SI1129088T1 (sl) 2008-08-31
CA2375201A1 (en) 2000-12-28
ES2426985T3 (es) 2013-10-28
PT1129088E (pt) 2008-05-05
DE60038481T2 (de) 2009-04-09
NO20016087L (no) 2001-12-13
NO20016087D0 (no) 2001-12-13
KR20010071354A (ko) 2001-07-28
BRPI0011674B8 (pt) 2021-05-25
US7339064B2 (en) 2008-03-04
US20090163553A1 (en) 2009-06-25
TWI275587B (en) 2007-03-11
EP2343289A1 (de) 2011-07-13
HUP0201659A2 (hu) 2002-11-28
US8552198B2 (en) 2013-10-08
KR20010052467A (ko) 2001-06-25
AR093609A2 (es) 2015-06-10
BR0011674A (pt) 2002-03-19
NZ515702A (en) 2003-07-25

Similar Documents

Publication Publication Date Title
ATE391126T1 (de) Kristalline form des (r)-2-(((3-methyl-4-(2,2,2- trifluorethoxy)-2-pyridinyl)methyl)sulfinyl)-1h benzimidazols
DK1177178T3 (da) Heterocyclisk substituerede benzimidazoler, deres fremstilling og anvendelse
IL160714A0 (en) Heterocyclic substituted 2-(4-phenoxy) pyridine derivatives and pharmaceutical compositions containing the same
BR9508292A (pt) Processos para a sintese enãncio-seletiva de um composto,(-)-5-metóxi-2[[(4-metóxi-3,5-dimetil-2-piridinil) metil]sulfinil]-1h-benzimidazol,(+)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h-benzimidazol,(+)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h benzimidazol composto e uso dos compostos
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
ATE284214T1 (de) Imidazo(1,2-a)-pyridinderivate als mglur5 antagonisten
EE200300385A (et) 3-(4-amidopürrool-2-üülmetülideen)-2-indolinooni derivaadid kui proteiini kinaasi inhibiitorid
EP2292612A3 (de) Kristalline und gelöste Formen von (R)-2-[[[3-methyl-4-(2, 2, 2-trifluorethoxy)-2-pyridinyl-]methyl-]sulfinyl-]-1H-benzoimidazol
NO20021540D0 (no) Sammensetninger med kontrollert frigivelse omfattende nimesulfid
AU2403802A (en) Benzimidazole derivatives
MXPA02008402A (es) Derivados de quinolina como antagonistas alfa-2.
NO20016246L (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
ATE253561T1 (de) 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
EE200200204A (et) Asendatud bensimidasooli preparaat
DK1254118T3 (da) Substituerede 1,2,3,4-tetrahudroquinolin-2-carboxylsyrederivater
EE200100646A (et) Melagatraani peaaegu kristalne vorm
AU2000258410A8 (en) New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
EE200000585A (et) 5,6-dikloro-2-(isopropüülamino)-1-(ß-L-ribofuranosüül)-1H-bensimidasooli vorm VI
IL136592A (en) (E)-3-[1-N-n-BUTYL-5-[2-(2-CARBOXYPHENYL) METHOXY-4-CHLOROPHENYL]-1H-PYRAZOL-4-YL]-2-[(5-METHOXY-2,3-DIHYDROBENZOFURAN-6- YL) METHYL]-PROP-2-ENOIC ACID MONOARGININYL SALT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
IS6758A (is) Kristallaform af 1-[6-klór-5-(tríflúormetýl)-2-pýridinýl]piperasín.hýdróklóríði
BR0015220A (pt) Procedimento melhorado para a preparação de derivados de benzimidazol adequados como fármacos antiulcerosos, principalmente omeprazol ou pantoprazol
ECSP003736A (es) Procedimiento mejorado para la preparacion de derivados de bencimidazol adecuados como farmacos antiulcerosos, particularmente omeprazol o pantoprazol
UY26420A1 (es) Procedimiento mejorado para la preparación de derivados bencimidazol adecuados como fármacos antiulcerosos, particularmente omeprazol o pantoprazol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1129088

Country of ref document: EP